阿司匹林

  • 基本信息
  • 制备方法及用途
  • 物化性质
  • 安全信息
  • 毒理性
  • MSDS
  • 结构与计算化学
  • 上游产品
  • 下游产品
  • 表征图谱

阿司匹林 基本信息

中文名称:
阿司匹林 
中文别名:
2-(乙酰氧基)苯甲酸;
阿斯匹林;
邻乙酰水杨酸;
O-乙酰基水杨酸;
阿司匹林;
乙酰水杨酸;
2-乙酰氧基苯甲酸 
英文名称:
Benzoicacid, 2-(acetyloxy)-
英文别名:
acetylsalicylic acid;
Aspirin;
2-Acetoxybenzoic acid,O-Acetylsalicylic acid,ASA;
O-acetyl salicylic acid;
Aspro;
aspirin;
2-(acetyloxy)benzoic acid;
2-Acetoxybenzoic acid,O-Acetylsalicyl;
Adiro;
Aspr;
O-Acetylsalicylic acid;
Bayer;
ASA;
2-Acetoxybenzoic acid;
Xaxa;
ECM;
Aspec;
Acetylsalicylic acid;
Novid;
ronal 
CAS No.:
50-78-2
分 子 式:

C9H8O4

分 子 量:
180.16
精确分子量:
180.04200
PSA:
63.60000
MDL:
MFCD00002430
EINECS:
200-064-1
BRN:
779271
InChI:
InChI=1/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)/p-1
危险品标志:


harmfulxn

风险术语:

R22R36/37/38:

安全术语:

S26S36/37/39

分子结构式:
SDS:
查看

阿司匹林 制备方法及用途

制备方法

1.水杨酸乙酰化而得:在反应罐中加乙酐(加料量为水杨酸总量的0.7889倍),再加入三分之二量的水杨酸,搅拌升温,在81-82℃反应40-60min。降温至81-82℃保温反应2h。检查游离水杨酸合格后,降温至13℃,析出结晶,甩滤,水洗甩干,于65-70℃气流干燥,得乙酰水杨酸。2.制法:于干燥的反应瓶中,加入干燥的水杨酸(2)25g(0.18mol),醋酸酐38g(0.37mol),浓硫酸1mL,于60℃水浴中反应30min。冷却后倒入400mL水中,充分搅拌,过滤、水洗。用1:1的稀醋酸重结晶①,得乙酰水杨酸(1)32g,收率98%。注:①也可用如下方法提纯:将粗产品溶于少量热乙醇中,再将热乙醇溶液慢慢加入2.5倍体积的热水中,形成透明溶液,慢慢冷却析出乙酰水杨酸针状结晶。3.制法:于反应瓶中加入干燥的水杨酸(2)25g(0.18mol),干燥的吡啶18mL,摇动使之溶解。慢慢滴加乙酰氯21g(0.28mol),反应放热,控制反应温度不超过60℃。加完后继续反应10min。冷却,倒入60mL冷水中,析出固体。抽滤、水洗,再用1:1的稀醋酸重结晶,得乙酰水杨酸(1)22g,收率67.5%。mp136~138℃(128~135℃部分分解)。

合成制备方法

1.水杨酸乙酰化而得:在反应罐中加乙酐(加料量为水杨酸总量的0.7889倍),再加入三分之二量的水杨酸,搅拌升温,在81-82℃反应40-60min。降温至81-82℃保温反应2h。检查游离水杨酸合格后,降温至13℃,析出结晶,甩滤,水洗甩干,于65-70℃气流干燥,得乙酰水杨酸。

2.制法:

于干燥的反应瓶中,加入干燥的水杨酸(2)25g(0.18mol),醋酸酐38g(0.37mol),浓硫酸1mL,于60℃水浴中反应30min。冷却后倒入400mL水中,充分搅拌,过滤、水洗。用1:1的稀醋酸重结晶,得乙酰水杨酸(1)32g,收率98%。注:①也可用如下方法提纯:将粗产品溶于少量热乙醇中,再将热乙醇溶液慢慢加入2.5倍体积的热水中,形成透明溶液,慢慢冷却析出乙酰水杨酸针状结晶。[1]

3.制法:

于反应瓶中加入干燥的水杨酸(2)25g(0.18mol),干燥的吡啶18mL,摇动使之溶解。慢慢滴加乙酰氯21g(0.28mol),反应放热,控制反应温度不超过60℃。加完后继续反应10min。冷却,倒入60mL冷水中,析出固体。抽滤、水洗,再用1:1的稀醋酸重结晶,得乙酰水杨酸(1)22g,收率67.5%。mp136~138℃(128~135℃部分分解)。[2]

用途简介

产品是应用最早,最广和最普通解热镇痛药抗风湿药。具有解热、镇痛、抗炎、抗风湿和抗血小板聚集等多方面的药理作用,发挥药效迅速,药效稳定,超剂量易于诊断和处理,很少发生过敏反应。常用于感冒发热,头痛、神经痛关节痛、肌肉痛、风湿热、急性内湿性关节炎、类风湿性关节炎及牙痛等。是《国家基本药物目录》列入的品种乙酰水杨酸也是其他药物的中间体。

用途

1.乙酰水杨酸是制备杀鼠剂中间体4-羟基香豆素的原料。

2.用于制造室外及有强光照射的结构件、器械部件,如汽车车身、农机部件、电表和电灯罩、道路标记等

3.解热镇痛药,用于发热、疼痛及类风湿关节炎等,是应用最早,最广和最普通解热镇痛药抗风湿药。具有解热、镇痛、抗炎、抗风温和抗血小板聚集等多方面的药理作用,发挥药效迅速,药效肯定,超剂量易于诊断和处理,很少发生过敏反应。常用于感冒发热,头痛、神经痛关节痛、肌肉痛、风湿热、急性内湿性关节炎、类风湿性关节炎及牙痛等。是《国家基本药物目录》列入的品种乙酰水杨酸也是其他药物的中间体。

4.制药工业,有机合成,检测锰的试剂。

阿司匹林 物化性质

外观与性状:
白色至灰白色结晶粉末
密度:
1.35
熔点:
134-136 °C(lit.)
沸点:
140ºC
闪点:
250 °C
水溶解性:
3.3 g/L (20 ºC)
存储条件/存储方法:
库房通风低温干燥,与氧化剂、食品添加剂分开存放
稳定性相关:

1.口服有毒,大量使用应穿适当的防护服。

其它信息:

1.       性状:白色针状或片状结晶。无气味。微带酸味在干燥空气中稳定,在潮湿空气中逐渐水解成水杨酸和乙酸。

2.       密度(g/mL,25/4℃):1.1872154

3.      相对密度(20℃,4℃):1.40

4.       熔点(ºC):135

5.       沸点(ºC,常压):未确定

6.       沸点(ºC, 5.2kPa):未确定

7.       折射率:未确定

8.       闪点(ºC):未确定

9.       比旋光度(º ):未确定

10.    自燃点或引燃温度(ºC):未确定

11.    蒸气压(kPa,25ºC):未确定

12.    饱和蒸气压(kPa,60ºC):未确定

13.    燃烧热(KJ/mol):未确定

14.    临界温度(ºC):未确定

15.    临界压力(KPa):未确定

16.    油水(辛醇/水)分配系数的对数值:未确定

17.    爆炸上限(%,V/V):未确定

18.    爆炸下限(%,V/V):未确定

19.    溶解性: 溶于乙醇、乙醚,微溶于水。

阿司匹林 安全信息

包装等级:
III
海关代码:
3004909090
WGK_Germany:
1
德国有关水污染物质的分类清单
危险类别码:
R22;R36/37/38
安全说明:
S26-S36/37/39
RTECS号:
VO0700000
安全标志:
S26:万一接触眼睛,立即使用大量清水冲洗并送医诊治。
危险标志:
Xn:Harmful

阿司匹林 毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :
VO0700000
CHEMICAL NAME :
Salicylic acid, acetate
CAS REGISTRY NUMBER :
50-78-2
BEILSTEIN REFERENCE NO. :
0779271
LAST UPDATED :
199712
DATA ITEMS CITED :
105
MOLECULAR FORMULA :
C9-H8-O4
MOLECULAR WEIGHT :
180.17
WISWESSER LINE NOTATION :
QVR BOV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
10 mg/kg/1D-I
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - acute pulmonary edema Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - urine volume decreased
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
857 mg/kg
TOXIC EFFECTS :
Behavioral - coma Lungs, Thorax, or Respiration - respiratory stimulation
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
525 mg/kg/5D-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
480 mg/kg/5D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Biochemical - Metabolism (Intermediary) - other
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
1625 mg/kg
TOXIC EFFECTS :
Behavioral - coma Nutritional and Gross Metabolic - body temperature increase
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - infant
DOSE/DURATION :
120 mg/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - respiratory stimulation Kidney, Ureter, Bladder - hematuria Nutritional and Gross Metabolic - dehydration
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
104 mg/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - acute pulmonary edema Gastrointestinal - nausea or vomiting Blood - hemorrhage
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
39 mg/kg/13D-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
669 mg/kg/11D
TOXIC EFFECTS :
Liver - liver function tests impaired
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
2880 mg/kg/8W
TOXIC EFFECTS :
Sense Organs and Special Senses (Ear) - tinnitus Gastrointestinal - nausea or vomiting Gastrointestinal - decreased motility or constipation
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
800 mg/kg
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Musculoskeletal - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
480 mg/kg/7D-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Ear) - tinnitus Behavioral - somnolence (general depressed activity) Gastrointestinal - other changes
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
294 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Rectal
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
4550 mg/kg
TOXIC EFFECTS :
Brain and Coverings - encephalitis Behavioral - coma Cardiac - arrhythmias (including changes in conduction)
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
340 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Rectal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
790 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
250 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
167 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1020 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
700 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Lungs, Thorax, or Respiration - respiratory depression
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
681 mg/kg
TOXIC EFFECTS :
Behavioral - analgesia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
1010 mg/kg
TOXIC EFFECTS :
Behavioral - changes in motor activity (specific assay)
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
1075 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Behavioral - tremor
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - hamster
DOSE/DURATION :
3500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - species unspecified
DOSE/DURATION :
1750 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
200 mg/kg/4D-I
TOXIC EFFECTS :
Gastrointestinal - ulceration or bleeding from stomach
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
8127 mg/kg/43W-C
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes in urine composition
TYPE OF TEST :
TCLo - Lowest published toxic concentration
ROUTE OF EXPOSURE :
Inhalation
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
25 mg/m3/4H/17W-I
TOXIC EFFECTS :
Brain and Coverings - recordings from specific areas of CNS Blood - change in clotting factors Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
9500 mg/kg/3W-I
TOXIC EFFECTS :
Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
700 mg/kg
SEX/DURATION :
female 35-36 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
546 mg/kg
SEX/DURATION :
female 37-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - other postnatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
546 mg/kg
SEX/DURATION :
female 37-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
17550 mg/kg
SEX/DURATION :
female 12-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
100 mg/kg
SEX/DURATION :
female 37 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - other neonatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
17280 mg/kg
SEX/DURATION :
female 1-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - Apgar score (human only)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
189 mg/kg
SEX/DURATION :
female 12-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
1200 mg/kg
SEX/DURATION :
female 20 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1 gm/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2100 mg/kg
SEX/DURATION :
male 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
500 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
200 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
10 mg/kg
SEX/DURATION :
female 22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - live birth index (measured after birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
500 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
125 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1 gm/kg
SEX/DURATION :
female 3 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1800 mg/kg
SEX/DURATION :
male 12 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
380 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
300 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
3500 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intrauterine
DOSE :
2 mg/kg
SEX/DURATION :
female 4 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1200 mg/kg
SEX/DURATION :
female 8-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
800 mg/kg
SEX/DURATION :
female 17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
19200 mg/kg
SEX/DURATION :
female 6-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - other neonatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2500 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
3200 mg/kg
SEX/DURATION :
female 23-30 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - respiratory system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
3 gm/kg
SEX/DURATION :
female 20-34 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
300 mg/kg
SEX/DURATION :
female 10-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
800 mg/kg
SEX/DURATION :
female 8-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1800 mg/kg
SEX/DURATION :
female 8-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1750 mg/kg
SEX/DURATION :
female 6-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
600 mg/kg
SEX/DURATION :
female 2 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
11250 mg/kg
SEX/DURATION :
female 16-30 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
Sister chromatid exchange

MUTATION DATA

TYPE OF TEST :
Cytogenetic analysis
TEST SYSTEM :
Rodent - hamster Lung
REFERENCE :
GMCRDC Gann Monograph on Cancer Research. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) No. 11- 1971- Volume(issue)/page/year: 27,95,1981 *** REVIEWS *** ACGIH TLV-TWA 5 mg/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 TOXICOLOGY REVIEW BCSTB5 Biochemical Society Transactions. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1973- Volume(issue)/page/year: 2,695,1974 TOXICOLOGY REVIEW DICPBB Drug Intelligence and Clinical Pharmacy. (POB 42435, Cincinnati, OH 45242) V.3- 1969- Volume(issue)/page/year: 9,350,1975 TOXICOLOGY REVIEW DICPBB Drug Intelligence and Clinical Pharmacy. (POB 42435, Cincinnati, OH 45242) V.3- 1969- Volume(issue)/page/year: 8,690,1974 TOXICOLOGY REVIEW PLMJAP Pahlavi Medical Journal. (Shiraz, Iran) V.1-9, 1970-78. Volume(issue)/page/year: 6,160,1975 TOXICOLOGY REVIEW JPHAA3 Journal of the American Pharmaceutical Association. (Washington, DC) V.1-28, 1912-39; New series: V.1-17, 1961-77. Volume(issue)/page/year: NS16,147,1976 TOXICOLOGY REVIEW AUHPAI Australian Journal of Hospital Pharmacy. (B.R. Miller, POB 125, Heidelberg, Vic., Australia) V.1- 1971- Volume(issue)/page/year: 3(3),100,1973 TOXICOLOGY REVIEW JRPMAP Journal of Reproductive Medicine. (2 Jacklynn Ct., St. Louis, MO 63132) V.3- 1969- Volume(issue)/page/year: 12,27,1974 TOXICOLOGY REVIEW CLCHAU Clinical Chemistry (Winston-Salem, NC). (American Assoc. for Clinical Chemistry, 1725 K St., NW, Washington, DC 20006) V.1- 1955- Volume(issue)/page/year: 19,361,1973 TOXICOLOGY REVIEW AJMEAZ American Journal of Medicine. (Technical Pub., 875 Third Ave., New York, NY 10022) V.1- 1946- Volume(issue)/page/year: 38,409,1965 TOXICOLOGY REVIEW ATXKA8 Archiv fuer Toxikologie. (Berlin, Fed. Rep. Ger.) V.15-31, 1954-74. For publisher information, see ARTODN. Volume(issue)/page/year: 28,135,1971 TOXICOLOGY REVIEW AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 141,358,1981 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-AUSTRALIA:TWA 5 mg/m3 JAN 1993 OEL-BELGIUM:TWA 5 mg/m3 JAN 1993 OEL-DENMARK:TWA 5 mg/m3 JAN 1993 OEL-THE NETHERLANDS:TWA 5 mg/m3 JAN 1993 OEL-RUSSIA:STEL 0.5 mg/m3 JAN 1993 OEL-SWITZERLAND:TWA 5 mg/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 5 mg/m3 JAN 1993 OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGIH TLV *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO ACETYLSALICYLIC ACID-air:10H TWA 5 mg/m3 REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992 NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84517 No. of Facilities: 1746 (estimated) No. of Industries: 12 No. of Occupations: 16 No. of Employees: 10452 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X1189 No. of Facilities: 27 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 191 (estimated) No. of Female Employees: 82 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84517 No. of Facilities: 491 (estimated) No. of Industries: 9 No. of Occupations: 22 No. of Employees: 10776 (estimated) No. of Female Employees: 6083 (estimated)
毒理学数据:

急性毒性:

口腔    LD50     700mg/kg(dog)

                 1075mg/kg(guinea pig)

                 3500mg/kg(ham)

                 1750mg/kg(mam)

                 250mg/kg(mus)

                 200mg/kg(rat)

                 1010mg/kg(rbt)

  LDLo     104mg/kg(chd)

主要的刺激性影响:

在皮肤上面:刺激皮肤和粘膜。

在眼睛上面:刺激的影响

致敏作用:没有已知的敏化作用。

生态数据:

总括注解 

水危害级别1(德国规例)(通过名单进行自我评估)该物质对水有稍微危害的。

 不要让未稀释或大量的产品接触地下水、水道或污水系统。 

若无政府许可,勿将材料排入周围环境。

阿司匹林 MSDS


模块 1. 化学品
  1.1 产品标识符
    : 乙酰水杨酸
    产品名称
    : Vetec
  1.2 鉴别的其他方法
    无数据资料
  1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
    仅用于研发。不作为药品、家庭或其它用途。

模块 2. 危险性概述
  2.1 GHS-分类
    急性毒性, 经口 (类别 3)
    皮肤刺激 (类别 2)
    眼睛刺激 (类别 2A)
    特异性靶器官系统毒性(一次接触) (类别 3)
  2.2 GHS 标记要素,包括预防性的陈述
    象形图
    警示词        危险    
    危险申明
    H301        吞咽会中毒    
    H315        造成皮肤刺激。    
    H319        造成严重眼刺激。    
    H335        可能引起呼吸道刺激。    
    警告申明
    预防措施
    P261        避免吸入粉尘/烟/气体/烟雾/蒸气/喷雾.    
    P264        操作后彻底清洁皮肤。    
    P270        使用本产品时不要进食、饮水或吸烟。    
    P271        只能在室外或通风良好之处使用。    
    P280        穿戴防护手套/ 眼保护罩/ 面部保护罩。    
    事故响应
    P301 + P310        如果吞下去了: 立即呼救解毒中心或医生。    
    P302 + P352        如果皮肤接触:用大量肥皂和水清洗。    
    P304 + P340        如吸入: 将患者移到新鲜空气处休息,并保持呼吸舒畅的姿势。    
    P305 + P351 + P338        如与眼睛接触,用水缓慢温和地冲洗几分钟。如戴隐形眼镜并可方便地取    
    出,取出隐形眼镜,然后继续冲洗.
    P312        如感觉不适,呼救中毒控制中心或医生.    
    P321        具体处置(见本标签上提供的急救指导)。    
    P330        漱口。    
    P332 + P313        如觉皮肤刺激:求医/就诊。    
    P337 + P313        如仍觉眼睛刺激:求医/就诊。    
    P362        脱掉沾污的衣服,清洗后方可再用。    
    安全储存
    P403 + P233        存放于通风良的地方。 保持容器密闭。    
    P405        存放处须加锁。    
    废弃处置
    P501        将内容物/ 容器处理到得到批准的废物处理厂。    
  2.3 其它危害物 - 无

模块 3. 成分/组成信息
  3.1 物 质
    : C9H8O4
    分子式
    : 180.16 g/mol
    分子量
    组分        浓度或浓度范围    
    O-Acetylsalicylic acid
    <=100%
    化学文摘登记号(CAS        50-78-2    
    No.)        200-064-1    
    EC-编号

模块 4. 急救措施
  4.1 必要的急救措施描述
    一般的建议
    请教医生。 向到现场的医生出示此安全技术说明书。
    吸入
    如果吸入,请将患者移到新鲜空气处。 如呼吸停止,进行人工呼吸。 请教医生。
    皮肤接触
    用肥皂和大量的水冲洗。 请教医生。
    眼睛接触
    用大量水彻底冲洗至少15分钟并请教医生。
    食入
    切勿给失去知觉者通过口喂任何东西。 用水漱口。 请教医生。
  4.2 主要症状和影响,急性和迟发效应
    据我们所知,此化学,物理和毒性性质尚未经完整的研究。
  4.3 及时的医疗处理和所需的特殊处理的说明和指示
    无数据资料

模块 5. 消防措施
  5.1 灭火介质
    灭火方法及灭火剂
    用水雾,抗乙醇泡沫,干粉或二氧化碳灭火。
  5.2 源于此物质或混合物的特别的危害
    碳氧化物
  5.3 给消防员的建议
    如必要的话,戴自给式呼吸器去救火。
  5.4 进一步信息
    无数据资料

模块 6. 泄露应急处理
  6.1 作业人员防护措施、防护装备和应急处置程序
    使用个人防护用品。 避免粉尘生成。 避免吸入蒸气、烟雾或气体。 保证充分的通风。
    人员疏散到安全区域。 避免吸入粉尘。
  6.2 环境保护措施
    不要让产品进入下水道。
  6.3 泄漏化学品的收容、清除方法及所使用的处置材料
    收集和处置时不要产生粉尘。 扫掉和铲掉。 放入合适的封闭的容器中待处理。
  6.4 参考其他部分
    丢弃处理请参阅第13节。

模块 7. 操作处置与储存
  7.1 安全操作的注意事项
    避免接触皮肤和眼睛。 避免形成粉尘和气溶胶。
    在有粉尘生成的地方,提供合适的排风设备。
  7.2 安全储存的条件,包括任何不兼容性
    贮存在阴凉处。 使容器保持密闭,储存在干燥通风处。
  7.3 特定用途
    无数据资料

模块 8. 接触控制和个体防护
  8.1 容许浓度
    最高容许浓度
    组分        化学文摘登        值        容许浓度        基准    
    记号(CAS
    No.)
    O-Acetylsalicylic        50-78-2        PC-        5 mg/m3        工作场所有害因素职业接触限值 -    
    acid        TWA        化学有害因素    
  8.2 暴露控制
    适当的技术控制
    根据良好的工业卫生和安全规范进行操作。 休息前和工作结束时洗手。
    个体防护设备
    眼/面保护
    带有防护边罩的安全眼镜符合 EN166要求请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟)
    检测与批准的设备防护眼部。
    皮肤保护
    戴手套取 手套在使用前必须受检查。
    请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
    使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
    所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
    完全接触
    物料: 丁腈橡胶
    最小的层厚度 0.11 mm
    溶剂渗透时间: 480 min
    测试过的物质Dermatril® (KCL 740 / Z677272, 规格 M)
    飞溅保护
    物料: 丁腈橡胶
    最小的层厚度 0.11 mm
    溶剂渗透时间: 480 min
    测试过的物质Dermatril® (KCL 740 / Z677272, 规格 M)
,     测试方法 EN374
    如果以溶剂形式应用或与其它物质混合应用,或在不同于EN
    374规定的条件下应用,请与EC批准的手套的供应商联系。
    这个推荐只是建议性的,并且务必让熟悉我们客户计划使用的特定情况的工业卫生学专家评估确认才可.
    这不应该解释为在提供对任何特定使用情况方法的批准.
    身体保护
    全套防化学试剂工作服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。
    呼吸系统防护
    如须暴露于有害环境中,请使用P95型(美国)或P1型(欧盟 英国
    143)防微粒呼吸器。如需更高级别防护,请使用OV/AG/P99型(美国)或ABEK-P2型 (欧盟 英国 143)
    防毒罐。
    呼吸器使用经过测试并通过政府标准如NIOSH(US)或CEN(EU)的呼吸器和零件。

模块 9. 理化特性
  9.1 基本的理化特性的信息
    a) 外观与性状
    形状: 粉末
    颜色: 白色
    b) 气味
    无数据资料
    c) 气味阈值
    无数据资料
    d) pH值
    3.5 在 2.5 g/l 在 20 °C
    e) 熔点/凝固点
    熔点/凝固点: 138 - 140 °C
    f) 沸点、初沸点和沸程
    无数据资料
    g) 闪点
    250 °C - 闭杯
    h) 蒸发速率
    无数据资料
    i) 易燃性(固体,气体)
    无数据资料
    j) 高的/低的燃烧性或爆炸性限度 无数据资料
    k) 蒸气压
    无数据资料
    l) 蒸汽密度
    无数据资料
    m) 密度/相对密度
    无数据资料
    n) 水溶性
    无数据资料
    o) n-辛醇/水分配系数
    辛醇--水的分配系数的对数值: 1.19
    p) 自燃温度
    无数据资料
    q) 分解温度
    无数据资料
    r) 粘度
    无数据资料

模块 10. 稳定性和反应活性
  10.1 反应性
    无数据资料
  10.2 稳定性
    无数据资料
  10.3 危险反应
    无数据资料
  10.4 应避免的条件
    加热。 暴露在光照下。
  10.5 不相容的物质
    强氧化剂, 强酸, 强碱
  10.6 危险的分解产物

模块 11. 毒理学资料
  11.1 毒理学影响的信息
    急性毒性
    半数致死剂量 (LD50) 经口 - 大鼠 - 1,500 mg/kg
    半数致死剂量 (LD50) 腹膜内的 - 大鼠 - 340 mg/kg
    半数致死剂量 (LD50) 腹膜内的 - 小鼠 - 167 mg/kg
    皮肤刺激或腐蚀
    无数据资料
    眼睛刺激或腐蚀
    无数据资料
    呼吸道或皮肤过敏
    无数据资料
    生殖细胞致突变性
    无数据资料
    致癌性
    IARC:
    此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。
    生殖毒性
    无数据资料
    从实验动物的结果看,过度接触能导致生殖紊乱
    特异性靶器官系统毒性(一次接触)
    吸入 - 可能引起呼吸道刺激。
    特异性靶器官系统毒性(反复接触)
    无数据资料
    吸入危险
    无数据资料
    潜在的健康影响
    吸入        吸入可能有害。 引起呼吸道刺激。    
    摄入        误吞对人体有害。    
    皮肤        通过皮肤吸收可能有害。 造成皮肤刺激。    
    眼睛        造成严重眼刺激。    
    接触后的征兆和症状
    据我们所知,此化学,物理和毒性性质尚未经完整的研究。
    附加说明
    化学物质毒性作用登记: 无数据资料

模块 12. 生态学资料
  12.1 生态毒性
    对鱼类的毒性        半数致死浓度(LC50) - 高体雅罗鱼 (金雅罗鱼) - > 1,000 mg/l - 48 h    
    对水蚤和其他水生无脊        半数效应浓度(EC50) - 水蚤 - > 100 mg/l - 48 h    
    椎动物的毒性
    细菌毒性        半数致死浓度(LC50) - 细菌 - > 10,000 mg/l - 48 h    
  12.2 持久性和降解性
    生物降解能力
    备注: 预计可生物降解
  12.3 潜在的生物累积性
    无数据资料
  12.4 土壤中的迁移性
    无数据资料
  12.5 PBT 和 vPvB的结果评价
    无数据资料
  12.6 其它不良影响
    无数据资料

模块 13. 废弃处置
  13.1 废物处理方法
    产品
    将剩余的和不可回收的溶液交给有许可证的公司处理。
    与易燃溶剂相溶或者相混合,在备有燃烧后处理和洗刷作用的化学焚化炉中燃烧
    受污染的容器和包装
    按未用产品处置。

模块 14. 运输信息
  14.1 联合国危险货物编号
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -    
  14.2 联合国运输名称
    欧洲陆运危规: 非危险货物
    国际海运危规: 非危险货物
    国际空运危规: 非危险货物
  14.3 运输危险类别
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -    
  14.4 包裹组
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -    
  14.5 环境危险
    欧洲陆运危规: 否        国际海运危规        国际空运危规: 否    
    海洋污染物(是/否): 否
  14.6 对使用者的特别提醒
    无数据资料


模块 15 - 法规信息
N/A


模块16 - 其他信息
N/A

阿司匹林 分子结构与计算化学数据

分子结构数据

1、  摩尔折射率:44.52

2、  摩尔体积(cm3/mol):139.5

3、  等张比容(90.2K):370.9

4、  表面张力(dyne/cm):49.8

5、  极化率(10-24cm3):17.65

计算化学数据

1、   疏水参数计算参考值(XlogP):1.2

2、   氢键供体数量:1

3、   氢键受体数量:4

4、   可旋转化学键数量:3

5、   互变异构体数量:

6、   拓扑分子极性表面积(TPSA):63.6

7、   重原子数量:13

8、   表面电荷:0

9、   复杂度:212

10、同位素原子数量:0

11、确定原子立构中心数量:0

12、不确定原子立构中心数量:0

13、确定化学键立构中心数量:0

14、不确定化学键立构中心数量:0

15、共价键单元数量:1

推荐供应商更多供应商>>

佛山信航生物科技有限公司

产品介绍:
产品名称:阿司匹林 Cas号:50-78-2 纯度:99.6% 包装信息:
联系方式:
联系人:刘 电话:17725670492 手机:17725670492

株洲森特生物科技有限公司

产品介绍:
产品名称:阿司匹林 Cas号:50-78-2 纯度:医药级99% 包装信息:25kg/编织袋
联系方式:
联系人:南佩 电话:18873303856 手机:18873303856

中山联久生物科技有限公司

产品介绍:
产品名称:阿司匹林 Cas号:50-78-2 纯度:99% 包装信息:25KG/牛皮纸袋
联系方式:
联系人:王彩 电话:18125350267 手机:18125350267

湖北鑫鸣泰化学有限公司

产品介绍:
产品名称:阿司匹林 Cas号:50-78-2 纯度:99% 包装信息:25kg /桶
联系方式:
联系人:刘经理 电话:027-51833411 手机:13237166274

武汉联商网科技有限公司

产品介绍:
产品名称:阿司匹林 Cas号:50-78-2 纯度:医药级99.6% 包装信息:25KG/牛皮纸袋,白色粉状,医药级99.6%
联系方式:
联系人:熊经理 电话:18872220794 手机:18872220794

湖北鑫鸣泰化学有限公司

产品介绍:
产品名称:阿司匹林 Cas号:50-78-2 纯度:99% 包装信息:100Kg,200Kg
联系方式:
联系人:黄 电话:13264726139 手机:13264726139

湖北远成药业有限公司

产品介绍:
产品名称:阿司匹林 Cas号:50-78-2 纯度:99% 包装信息:25kg/纸板桶
联系方式:
联系人:陈剑强 电话:059-25565683 手机:15172158042

厦门盛朗赛创生物科技有限公司

产品介绍:
产品名称:阿司匹林 Cas号:50-78-2 纯度:99% 包装信息:25KG/牛皮纸袋
联系方式:
联系人:陈剑强 电话:18159288165 手机:18159288165

佛山市嘉跃生物科技有限公司

产品介绍:
产品名称:阿司匹林 Cas号:50-78-2 纯度:医药级99% 包装信息:25KG/复合编织袋 可拆
联系方式:
联系人:彭 电话:0731-85238073 手机:17373192935

珠海市双博杰科技有限公司

产品介绍:
产品名称:邻乙酰水杨酸 Cas号:50-78-2 纯度:99% 包装信息:1
联系方式:
联系人:胡惠 电话:18186437087 手机:18186437087